Legend Biotech Corp (LEGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.10B
Last updated: Nov 17, 2026 at 4:39 PM ET
Legend Biotech Corp (LEGN) Statistics
Legend Biotech (LEGN) has a market cap of $3.10B. Revenue grew 49.45% over the last 12 months from the 12 months before. Its share count is up 4.96% from a year earlier.
Total Valuation
| Market Cap | $3.10B |
|---|---|
| Latest price (Nov 17, 2026) | $16.11 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.3x and 2.5x.
| P/E Ratio | 268.5x |
|---|---|
| P/S Ratio | 2.3x |
| Forward P/S | 2.2x |
| P/B Ratio | 2.5x |
| P/TBV Ratio | 2.6x |
Price Statistics
The stock is down 46.81% over 52 weeks and trades 16.83% below its 50-day average.
| Beta (1Y) | 0.67 |
|---|---|
| 52-Week Change | -46.81% |
| 1-Month Change | -13.62% |
| 3-Month Change | -28.72% |
| 6-Month Change | -40.20% |
| 5-Year Change | -58.80% |
| Total Return (1Y) | -46.81% |
| Total Return (3Y CAGR) | -37.04% |
| Total Return (5Y CAGR) | -21.75% |
| Return vs SPY (1Y) | -56.80% |
| Max Drawdown (1Y) | -55.93% |
| Max Drawdown (3Y) | -77.15% |
| Sharpe Ratio (1Y) | -0.80 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $19.37 |
| 200-Day Average | $22.18 |
| 52-Week Range | $15.97 to $37.50 |
| RSI (14 Days) | 33.8 |
| Average Volume (20 Days) | 2.61M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.95x current liabilities.
| Current Ratio | 3.95x |
|---|---|
| Quick Ratio | 3.82x |
| Interest Coverage | 3.27x |
Returns and Efficiency
Return on equity is -0.02% over the last 12 months, against a 5-year average of -40.14%.
| Return on Equity (ROE) | -0.02% |
|---|---|
| Return on Assets (ROA) | -0.01% |
| Return on Capital Employed (ROCE) | 3.54% |
| ROE (5Y Average) | -40.14% |
| ROA (5Y Average) | -25.07% |
| ROIC (5Y Average) | -29.36% |
| Asset Turnover | 0.80x |
| Inventory Turnover | 14.38x |
| Receivables Turnover | 6.52x |
| Cash Conversion Cycle | 35 days |
Scores
LEGN has an Altman Z-Score of 4.49, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.49 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $1.36B over the last 12 months.
| Revenue | $1.36B |
|---|---|
| Revenue Growth (YoY) | +49.45% |
| Gross Profit | $774.12M |
| Operating Income | $34.10M |
| Pretax Income | $32.20M |
| Net Income | -$215.00K |
| EBITDA | $99.55M |
| EBIT | $49.28M |
| Reported EPS (TTM) | $0.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 75.60% of the $1.68B in total assets.
| Cash and Equivalents | $460.70M |
|---|---|
| Working Capital | $855.20M |
| Shareholder Equity | $1.27B |
| Tangible Book Value | $1.20B |
| Total Assets | $1.68B |
| Total Liabilities | $408.70M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $73.11M of capital spending, operating cash flow left -$320.91M of free cash flow.
| Operating Cash Flow | -$247.80M |
|---|---|
| Capital Expenditures | $73.11M |
| Free Cash Flow | -$320.91M |
| FCF Per Share | -$1.65 |
| Depreciation and Amortization | $50.27M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 2.51%.
| Gross Margin | 56.98% |
|---|---|
| Operating Margin | 2.51% |
| Pretax Margin | 2.37% |
| Net Margin | -0.02% |
| EBITDA Margin | 7.33% |
| EBIT Margin | 3.63% |
| FCF Margin | -23.62% |
| Gross Margin (5Y Average) | 63.30% |
Growth
Revenue grew 106.41% a year over 3 years.
| Revenue Growth (3Y CAGR) | +106.41% |
|---|---|
| Revenue Growth (5Y CAGR) | +68.83% |
Dividends and Yields
LEGN does not pay a dividend. Its free cash flow yield is -10.28%.
| Earnings Yield | 0.37% |
|---|---|
| FCF Yield | -10.28% |
| Shareholder Yield | 0.00% |
Peer Position
Against 6 similar companies, LEGN has the lowest P/S.
P/S RatioPeer median 11.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -78.40%
| P/S Ratio | 2.3x vs 11.9x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +49.45% vs -78.40% median |
Analyst Forecast
Consensus estimates put revenue growth at 22.22% a year over the next 5 fiscal years.
| Revenue Growth Forecast (5Y CAGR) | +22.22% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LEGN
What is LEGN's market cap?
Legend Biotech has a market cap of $3.10B.
What is LEGN's P/E ratio?
Legend Biotech has a trailing P/E ratio of 268.5x.
How many shares of LEGN are outstanding?
Legend Biotech has 193.80M shares outstanding. The count is up 4.96% from a year earlier.
Does LEGN pay a dividend?
No. Legend Biotech does not pay a dividend.
LEGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors